Browsing by Author "Arikan, Ayse"

Now showing 1 - 2 of 2

Citation - WoS: 1
Citation - Scopus: 1
Evaluation of Lateral Flow and Elisa Techniques for Detecting Igg and Igm Antibodies in Covid-19 Cases in Turkiye
(Who Eastern Mediterranean Regional Office, 2023) Arikan, Ayse; Doluca, Osman; Akhan, Sila; Sanlidag, Tamer; Sayan, Murat
Background: Antibody testing can complement molecular assays for detecting COVID-19.Aims: We evaluated the concurrence between lateral flow assay and enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).Methods: The study was conducted at Kocaeli University, Turkiye. We used a lateral flow assay and ELISA to test serum samples from COVID-19 cases, confirmed by polymerase chain reaction assays (study group) and pre-pandemic stored serum samples (control group). We used Deming regression to evaluate the antibody measurements.Results: The study group included 100 COVID-19 cases, and the control group included pre-pandemic samples from 156 individuals. The lateral flow assay detected immunoglobulin M (IgM) and G (IgG) antibodies in 35 and 37 study group samples. ELISA detected IgM nucleocapsid (N) antibodies in 18 samples, and IgG (N) and IgG spike 1 (S1) antibodies in 31 and 29 samples, respectively. None of the techniques detected antibodies in the control samples. Strong correlations were found between lateral flow IgG (N+ receptor-binding domain + S1) and ELISA IgG (S) (r = 0.93, P < 0.01) and ELISA IgG (N) (r = 0.81, P < 0.01). Weaker correlations were seen between ELISA IgG S and IgG N (r = 0.79, P < 0.01) and lateral flow assay and ELISA IgM (N) (r = 0.70, P < 0.01).Conclusion: Lateral flow assay and ELISA techniques gave consistent results for IgG/IgM antibody measurements towards spike and nucleocapsid proteins, suggesting that both methods can be used to detect COVID-19 where access to molecular test kits is difficult.
Citation - WoS: 2
Citation - Scopus: 2
Neumodx Random Access Molecular Diagnostic System for Detection and Quantification of Hepatitis B Virus in Clinical Samples
(J Infection Developing Countries, 2020) Arikan, Ayse; Sayan, Murat; Doluca, Osman
Introduction: Currently, several molecular assays are available to detect and quantify HBV DNA in clinical samples. We aimed to characterize and compare the clinical performance of newly designed NeuMoDx PCR to the existing artus PCR. Methodology: The plasma HBV DNA levels of 96 clinical and 5 external quality control samples were measured by NeuMoDx and artus assays simultaneously in Kocaeli University, Turkey. The linearity, agreement and the correlation between two assays were determined by Deming regression analysis, Bland-Altman plotting, the chi-square and the relative absolute error statistical analyzes. For all statistical analyzes, the XLSTAT statistical program was used. Results: The mean (standard deviation; SD) age was 45.07 +/- 12.29. HBsAg S/Co median (range) was 4,273.4 +/- 1,138.1 and ALT U/L median (range) was 27 +/- 16. The mean (SD) of HBV DNA was 1.46+E6 +/- 1.0+E4 for NeuMoDx and 1.54+E5 +/- 4.7 + E4 for artus assays. The Deming regression indicates a linear correlation (95% confidence). The chi-square test indicates strong correlation (p < 0.001). Bland-Altman analysis confirms that the measurement difference is acceptable. The relative absolute error analysis for artus showed relatively less and more consistent error rate. With 5 external quality check samples, the statistical significance was low (p = 0.566). Conclusions: The NeuMoDx HBV assay showed an excellent analytical performance by providing a rapid, high throughput technology in a random-access testing system in clinical samples and may be a new solution for viral load quantification in the management of HBV infections.